
    
      This is a Phase II, non-randomized, open-label, multi-center study conducted in the USA. The
      primary endpoint is to evaluate the use of long term adjuvant imatinib mesylate in patients
      at significant risk for recurrence following complete resection of primary GIST. A total of
      85 adult patients, 18 years of age and older will be enrolled.Participants will take 400 mg
      of imatinib mesylate daily by mouth for a total of 5 years. At the conclusion of the
      treatment period, patients will be followed for 2 years for survival, status of response and
      antineoplastic treatments and quality of life.
    
  